Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2025-07-18 00:00:00 ET · period of report 2025-07-16 · accession 0000950170-25-096947 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-18 | 2025-07-16 | SNDX | Metzger Michael A | CEO, Dir | S - Sale | $9.29 | -7,534 | 298.7K | -2% | -$70.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-16 | S | D | 7,534 | $9.29 | 298,661 | D | — | — | (F1) Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. |